Journal
JOURNAL OF LIPID RESEARCH
Volume 60, Issue 4, Pages 741-746Publisher
ELSEVIER
DOI: 10.1194/jlr.S092007
Keywords
nicotinic acid; sirtuins; mitochondria; cholesterol; dyslipidemia; HDL; LDL; kidney disease; fatty acid oxidation; lipid synthesis
Categories
Funding
- European Research Council [ERC-2017-ADG-787702]
- Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung [SNSF 31003A_179435]
- Ecole Polytechnique Federale de Lausanne
Ask authors/readers for more resources
Niacin, the first antidyslipidemic drug, has been at the center stage of lipid research for many decades before the discovery of statins. However, to date, despite its remarkable effects on lipid profiles, the clinical outcomes of niacin treatment on cardiac events is still debated. In addition to its historically well-defined interactions with central players of lipid metabolism, niacin can be processed by eukaryotic cells to synthesize a crucial cofactor, NAD(+). NAD(+) acts as a cofactor in key cellular processes, including oxidative phosphorylation, glycolysis, and DNA repair. More recently, evidence has emerged that NAD(+) also is an essential cosubstrate for the sirtuin family of protein deacylases and thereby has an impact on a wide range of cellular processes, most notably mitochondrial homeostasis, energy homeostasis, and lipid metabolism. NAD(+) achieves these remarkable effects through sirtuin-mediated deacetylation of key transcriptional regulators, such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, LXR, and SREBPs, that control these cellular processes. Here, we present an alternative point of view to explain niacin's mechanism of action, with a strong focus on the importance of how this old drug acts as a control switch of NAD(+)/sirtuin-mediated control of metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available